ArticleBritish journal of pharmacology2009
The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells.
Article in British journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Potential mechanisms and effects of AFB1-induced asthma: A comprehensive analysis based on network toxicology and molecular docking.PloS one · 2026Article
- A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting βPharmacology research & perspectives · 2025Article
- Aberrant Activation of Mast Cells: Molecular Mechanisms and Targets for Intervention.Clinical reviews in allergy & immunology · 2025Review
- Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.Computational and structural biotechnology journal · 2021Article
- G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.Pharmacological reviews · 2020Review
- Exchange protein directly activated by cAMP (Epac) protects against airway inflammation and airway remodeling in asthmatic mice.Respiratory research · 2019Article
- Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma.Journal of aerosol medicine and pulmonary drug delivery · 2016Article
- Functional desensitization of the β 2 adrenoceptor is not dependent on agonist efficacy.Pharmacology research & perspectives · 2015Article
- The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro.Mediators of inflammation · 2014Article
- New developments in the management of COPD: clinical utility of indacaterol 75 μg.International journal of chronic obstructive pulmonary disease · 2014Review
- Anti-inflammatory effects of β2 adrenergic receptor agonists in experimental acute lung injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2012Article
- Association of house dust mite-specific IgE with asthma control, medications and household pets.Asia Pacific allergy · 2011Article
- Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms.British journal of pharmacology · 2011Article
- Review
- Agonist efficacy and receptor desensitization: from partial truths to a fuller picture.British journal of pharmacology · 2009Review
- GPCR theme editorial.British journal of pharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe long-acting beta(2)-adrenoceptor agonist, indacaterol, has been developed as a bronchodilator for the therapeutic management of respiratory diseases. The aim of the present study was to determine whether indacaterol has any anti-inflammatory activity. To this end, the effects of indacaterol on human lung mast cell responses were investigated. EXPERIMENTAL APPROACH: The effects of indacaterol, and the alternative long-acting beta-agonists formoterol and salmeterol, were investigated on the IgE-dependent release and generation of histamine, cysteinyl-leukotrienes and prostaglandin D(2) from human lung mast cells. Moreover, the extent to which long-term (24-72 h) incubation of mast cells with long-acting beta-agonists impaired the subsequent ability of beta-agonists to inhibit mast cell responses was assessed. KEY
resultsIndacaterol was as potent and as efficacious as the full agonist, isoprenaline (EC(50), approximately 4 nmol x L(-1)), at inhibiting the IgE-dependent release of histamine from mast cells. Formoterol was a full agonist whereas salmeterol was a partial agonist as inhibitors of histamine release. All three long-acting beta-agonists were effective inhibitors of the IgE-dependent generation of cysteinyl-leukotrienes and prostaglandin D(2). Long-term incubation of mast cells with long-acting beta-agonists led to a reduction in the subsequent ability of beta-agonists to stabilize mast cell responses. This tendency to induce functional desensitization was least evident for indacaterol. CONCLUSIONS AND IMPLICATIONS: Indacaterol is an effective inhibitor of the release of mediators from human lung mast cells. This suggests that, as well as bronchodilation, mast cell stabilization may constitute an additional therapeutic benefit of indacaterol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.